- Home
- PSTV vs REVB Comparison
PSTV vs REVB Comparison
Compare PSTV & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- REVB
- Stock Information
- Founded
- PSTV 1996
- REVB 2020
- Country
- PSTV United States
- REVB United States
- Employees
- PSTV N/A
- REVB N/A
- Industry
- PSTV Medical/Dental Instruments
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- REVB Health Care
- Exchange
- PSTV Nasdaq
- REVB Nasdaq
- Market Cap
- PSTV 2.1M
- REVB 2.3M
- IPO Year
- PSTV N/A
- REVB N/A
- Fundamental
- Price
- PSTV $0.93
- REVB $2.51
- Analyst Decision
- PSTV Strong Buy
- REVB
- Analyst Count
- PSTV 3
- REVB 0
- Target Price
- PSTV $11.17
- REVB N/A
- AVG Volume (30 Days)
- PSTV 47.0M
- REVB 142.9K
- Earning Date
- PSTV 03-27-2025
- REVB 03-06-2025
- Dividend Yield
- PSTV N/A
- REVB N/A
- EPS Growth
- PSTV N/A
- REVB N/A
- EPS
- PSTV N/A
- REVB N/A
- Revenue
- PSTV $5,824,000.00
- REVB N/A
- Revenue This Year
- PSTV N/A
- REVB N/A
- Revenue Next Year
- PSTV N/A
- REVB N/A
- P/E Ratio
- PSTV N/A
- REVB N/A
- Revenue Growth
- PSTV 18.54
- REVB N/A
- 52 Week Low
- PSTV $0.24
- REVB $2.36
- 52 Week High
- PSTV $2.67
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- PSTV 46.88
- REVB 27.55
- Support Level
- PSTV $0.94
- REVB $2.51
- Resistance Level
- PSTV $1.77
- REVB $2.92
- Average True Range (ATR)
- PSTV 0.31
- REVB 0.25
- MACD
- PSTV -0.00
- REVB 0.02
- Stochastic Oscillator
- PSTV 27.68
- REVB 13.76
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).